Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis

INTRODUCTION: Second-generation androgen receptor inhibitors (SGARIs), namely enzalutamide, apalutamide, and darolutamide, are good for improving survival outcomes in prostate cancer patients, but some researchers have shown that using SGARIs increases side effects, which complicates clinicians’ cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiangyu, Wang, Qihua, Pan, Yang, Wang, Shangren, Li, Yuezheng, Zhang, Hao, Xu, Mingming, Zhou, Hang, Liu, Xiaoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034066/
https://www.ncbi.nlm.nih.gov/pubmed/36967752
http://dx.doi.org/10.3389/fendo.2023.1134719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034066/
https://www.ncbi.nlm.nih.gov/pubmed/36967752
http://dx.doi.org/10.3389/fendo.2023.1134719

Ejemplares similares